Role of biochemical markers in the management of osteoporosis

References

• Arceo-Mendoza RM, Camacho P. Prediction of fracture risk in patients with osteoporosis: a brief review. Womens Health (Lond Engl) 2015;11:477–84
   PubMedGoogle Scholar
• Miller PD, Siris ES, Barrett-Connor E, et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 2002;17:2222–30
   PubMed Web of Science ®Google Scholar
• Schuit SC, van der KM, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004;34:195–202
   PubMed Web of Science ®Google Scholar
• Hillier TA, Cauley JA, Rizzo JH, et al. The WHO absolute fracture risk models (FRAX): Do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res 2011;26:1774–82
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Vasikaran S, Cooper C. Official positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011;14:220–2
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
   PubMed Web of Science ®Google Scholar
• Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos Int 1997;7(Suppl 1):S3–7
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Johnston CC, Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444–50
   PubMed Web of Science ®Google Scholar
• Warming L, Christoffersen C, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Adverse effects of a SERM (levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003;44:189–99
   PubMed Web of Science ®Google Scholar
• Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222–9
   PubMed Web of Science ®Google Scholar
• Christiansen C, Chesnut CH III, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010;11:130
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923–34
   PubMed Web of Science ®Google Scholar
• Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 2008;19:339–48
   PubMed Web of Science ®Google Scholar
• Ausmanas MK, Holinka CF, Ling YS, Christiansen C. Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. Climacteric 2007;10:306–13
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS, Transbol I. Bone mass after withdrawal of oestrogen replacement. Lancet 1981;1:1053–4
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728–35
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459–61
   PubMed Web of Science ®Google Scholar
• Christiansen C. Selection of postmenopausal women for estrogen therapy. Postgrad Med 1989;Spec No:10–12
   Google Scholar
• Christiansen C, Riis BJ, Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987;1:1105–8
   PubMed Web of Science ®Google Scholar
• Christiansen C. Osteoporosis: diagnosis and management today and tomorrow. Bone 1995;17(5 Suppl):513–16S
   PubMed Web of Science ®Google Scholar
• Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 1996;19:9–12
   PubMed Web of Science ®Google Scholar
• Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991;303:961–4
   PubMed Web of Science ®Google Scholar
• Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology – implications for future treatments of osteoporosis. Endocr Rev 2011;32:31–63
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Qvist P, Christiansen C, Tanko LB. Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? Drugs 2006;66:1909–18
   PubMed Web of Science ®Google Scholar
• Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237–44
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009;14:181–202
   PubMed Web of Science ®Google Scholar
• Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864–8
   PubMed Web of Science ®Google Scholar
• Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022–5
   PubMed Web of Science ®Google Scholar
• Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998;44:2290–300
   PubMed Web of Science ®Google Scholar
• Fledelius C, Johnsen AH, Cloos PA, Bonde M, Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 1997;272:9755–63
   PubMed Web of Science ®Google Scholar
• Fledelius C, Kolding I, Qvist P, et al. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Scand J Clin Lab Invest 1997;57:73–83
   PubMed Web of Science ®Google Scholar
• Ravn P, Fledelius C, Rosenquist C, Overgaard K, Christiansen C. High bone turnover is associated with low bone mass in both pre- and postmenopausal women. Bone 1996;19:291–8
   PubMed Web of Science ®Google Scholar
• Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780–5
   PubMed Web of Science ®Google Scholar
• Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363–8
   PubMed Web of Science ®Google Scholar
• Andersson ML, Petersson IF, Karlsson KE, et al. Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. Ann Rheum Dis 2006;65:1490–4
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002;30:307–13
   PubMed Web of Science ®Google Scholar
• Henriksen K, Leeming DJ, Christiansen C, Karsdal MA. Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options. Womens Health (Lond Engl) 2011;7:689–98
   PubMedGoogle Scholar
• Cloos PA, Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J 2000;345:473–80
   PubMed Web of Science ®Google Scholar
• Okabe R, Inaba M, Nakatsuka K, et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 2004;22:127–31
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:32–8
   PubMed Web of Science ®Google Scholar
• Chaki O, Yoshikata I, Kikuchi R, et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res 2000;15:1537–44
   PubMed Web of Science ®Google Scholar
• Liesegang A. Possibilities of monitoring bone metabolism in ruminants – an overview of the methods in use. Acta Vet Scand Suppl 2003;97:23–8
   PubMedGoogle Scholar
• Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 2007;18:681–5
   PubMed Web of Science ®Google Scholar
• Rissanen JP, Suominen MI, Peng Z, Halleen JM. Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 2008;82:108–15
   PubMed Web of Science ®Google Scholar
• Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P, et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas 2009;64:188–92
   PubMed Web of Science ®Google Scholar
• Sun S, Karsdal MA, Bay-Jensen AC, et al. The development and characterization of an ELISA specifically detecting the active form of cathepsin K. Clin Biochem 2013;46:1601–6
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tanko LB. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006;62:781–92
   PubMed Web of Science ®Google Scholar
• Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391–420
   PubMed Web of Science ®Google Scholar
• Cejka D, Jager-Lansky A, Kieweg H, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2011;27:226–30
   PubMed Web of Science ®Google Scholar
• Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab 2011;96:1380–6
   Web of Science ®Google Scholar
• Modder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011;26:373–9
   PubMed Web of Science ®Google Scholar
• Butler JS, Murray DW, Hurson CJ, O'Brien J, Doran PP, O'Byrne JM. The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop Res 2011;29:414–18
   PubMed Web of Science ®Google Scholar
• Schaller S, Henriksen K, Hoegh-Andersen P, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005;3:553–80
   PubMed Web of Science ®Google Scholar
• Christgau S, Bitsch-Jensen O, Hanover BN, et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505–11
   PubMed Web of Science ®Google Scholar
• Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002;31:57–61
   PubMed Web of Science ®Google Scholar
• Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos Int 2000;11(Suppl 6):S45–54
   Google Scholar
• Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11(Suppl 6):S2–17
   PubMed Web of Science ®Google Scholar
• Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999;14:1404–10
   PubMed Web of Science ®Google Scholar
• Melton LJ, III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083–91
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531–8
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526–36
   PubMed Web of Science ®Google Scholar
• Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813–19
   PubMed Web of Science ®Google Scholar
• Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998;8:563–9
   PubMed Web of Science ®Google Scholar
• Bruyere O, Collette J, Delmas P, et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 2003;44:259–65
   PubMed Web of Science ®Google Scholar
• Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386–93
   PubMed Web of Science ®Google Scholar
• Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149–57
   PubMed Web of Science ®Google Scholar
• Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2010;26:530–7
   Web of Science ®Google Scholar
• Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20:1244–53
   PubMed Web of Science ®Google Scholar
• Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009;45:1053–8
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers – are they the cause or the consequence of the disease? Clin Biochem 2010;43:793–804
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2010;26:242–51
   Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Bay-Jensen AC, Henriksen K, Riis BJ, Christiansen C. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis – the effect of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 2010;11:125
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19–26
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 2007;40:723–9
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clack G, Rimmer M, et al. Effect of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 2010;25:463–71
   Google Scholar
• Karsdal MA, Henriksen K, Sorensen MG, et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005;166:467–76
   PubMed Web of Science ®Google Scholar
• Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004;19:1144–53
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267–76
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004;19:1531–8
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004;34:187–94
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141–51
   PubMed Web of Science ®Google Scholar
• Emkey R, Delmas PD, Bolognese M, et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther 2009;31:751–61
   PubMed Web of Science ®Google Scholar
• Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838–46
   PubMed Web of Science ®Google Scholar
• Delmas PD, Recker RR, Chesnut CH, III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792–8
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Pereda CA, Hannon RA, Naylor KE, Eastell R. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women. BJOG 2002;109:812–20
   PubMed Web of Science ®Google Scholar
• Naylor KE, Clowes JA, Finigan J, Paggiosi MA, Peel NF, Eastell R. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 2010;46:592–7
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Vignot E, Garnero P, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 1999;10:330–6
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis – a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060–6
   PubMed Web of Science ®Google Scholar
• Quesada-Gomez JM, Muschitz C, Gomez-Reino J, Greisen H, Andersen HS, Dimai HP. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial. Osteoporos Int 2010;22:2529–37
   PubMed Web of Science ®Google Scholar
• Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2009;25:937–47
   Web of Science ®Google Scholar
• Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. J Bone Miner Res 2011;26:1303–12
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009;45:833–42
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555–65
   PubMed Web of Science ®Google Scholar
• Black DM, Bouxsein ML, Palermo L, et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab 2008;93:2166–72
   PubMed Web of Science ®Google Scholar
• Henriksen K, Bohren KM, Bay-Jensen AC, Karsdal MA. Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? Biomarkers 2010;15:195–204
   PubMed Web of Science ®Google Scholar
• Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004;89:4923–8
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820–5
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil TN, Guvener DN. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523–30
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305–10
   PubMed Web of Science ®Google Scholar
• Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 2007;177:723–4
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963–72
   PubMed Web of Science ®Google Scholar
• Motyl KJ, Dick-de-Paula I, Maloney AE, et al. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone 2012;50:490–8
   PubMed Web of Science ®Google Scholar
• Henriksen K, Byrjalsen I, Qvist P, et al. Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 2011;27:392–401
   PubMed Web of Science ®Google Scholar
• Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000;11(Suppl 6):S30–44
   PubMedGoogle Scholar
• Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin Pharmacol 2008;8:5
   PubMedGoogle Scholar
• Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol 2008;8:12
   PubMedGoogle Scholar
• Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J Clin Pharmacol 2009;49:229–34
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Azria M, et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol 2009;67:413–20
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010;18:150–9
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol 2010;66:29–37
   PubMed Web of Science ®Google Scholar